53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
Authors:
- Fabienne SchochterFSFabienne Schochter
- Kim WernerKWKim Werner
- Cäcilia KöstlerCKCäcilia Köstler
- Anke FaulAFAnke Faul
- Marie TzschaschelMTMarie Tzschaschel
- Barbara AlberterBABarbara Alberter
- Volkmar MüllerVMVolkmar Müller
- Hans NeubauerHNHans Neubauer
- Tanja FehmTFTanja Fehm
- Thomas W.P. FriedlTFThomas W.P. Friedl
- Bernhard PolzerBPBernhard Polzer
- Wolfgang JanniWJWolfgang Janni
Open Access
Abstract
Evidence suggests that the DNA end-binding protein p53-binding protein 1 (53BP1) is down-regulated in subsets of breast cancer. Circulating tumor cells (CTCs) provide accessible “biopsy material” to track cell traits and functions and their alterations during treatment. Here, we prospectively monitored the 53BP1 status in CTCs from 67 metastatic breast cancer (MBC) patients with HER2- CTCs and known hormone receptor (HR) status of the primary tumor and/or metastases before, during, and at the end of chemotherapeutic treatment with Eribulin. Nuclear 53BP1 staining and genomic integrity were evaluated by immunocytochemical and whole-genome-amplification-based polymerase chain reaction (PCR) analysis, respectively. Comparative analysis of CTCs from patients with triple-negative and HR+ tumors revealed elevated 53BP1 levels in CTCs from patients with HR+ metastases, particularly following chemotherapeutic treatment. Differences in nuclear 53BP1 signals did not correlate with genomic integrity in CTCs at baseline or with nuclear γH2AX signals in MBC cell lines, indicating that 53BP1 detected features beyond DNA damage. Kaplan–Meier analysis revealed an increasing association between nuclear 53BP1-positivity and progression-free survival (PFS) during chemotherapy until the final visit. Our data suggest that 53BP1 detection in CTCs could be a useful marker to capture dynamic changes of chemotherapeutic responsiveness in triple-negative and HR+ MBC.Keywords
Funding Information
- Deutsche Krebshilfe (70112504)
- Deutsche Forschungsgemeinschaft (Research Training Group 2544)
This publication has 49 references indexed in Scilit:
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationNew England Journal of Medicine, 2018
- DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosisCancer Biology & Therapy, 2017
- Hereditary breast and ovarian cancer: new genes in confined pathwaysNature Reviews Cancer, 2016
- Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast CancerJournal of Clinical Oncology, 2015
- Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair GenesPLOS ONE, 2013
- A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway ChoiceMolecular Cell, 2013
- Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast CancerClinical Cancer Research, 2011
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancersNature Structural & Molecular Biology, 2010
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA BreaksCell, 2010
- Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial DesignClinical Breast Cancer, 2009